Lung cancer: Morphological and functional approach to screening, staging and treatment planning

Future Oncology

Volumn 6, Issue 3, 2010, Pages 367-380

  Coche, Emmanuel ^a   Lonneux, Max ^a   Geets, Xavier ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

CT; Diagnosis; FDG PET CT; Lung cancer; Lung nodule; MRI; Planning; Radiotherapy

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18;

CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; IMAGE PROCESSING; LUNG CANCER; MOLECULAR IMAGING; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; THORACOTOMY; TREATMENT PLANNING;

ADULT; AGED; DIAGNOSTIC IMAGING; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING;

EID: 77949463656     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.7     Document Type: Review

References (80)

1. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J. Clin. 49, 33-64 (1999).
2. Jemal A, Murray T, Ward E et al.: Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
3. Henschke CI, McCauley DI, Yankelevitz DF et al.: Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 354, 99-105 (1999).
4. Swensen SJ, Jett JR, Hartman TE et al.: Lung cancer screening with CT: Mayo Clinic experience. Radiology 226, 756-761 (2003).
5. Swensen SJ, Jett JR, Sloan JA et al.: Screening for lung cancer with low-dose spiral computed tomography. Am. J. Respir. Crit. Care Med. 165, 508-513 (2002).
6. Diederich S, Wormanns D, Semik M et al.: Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology 222, 773-781 (2002).
7. Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR: Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 289, 313-322 (2003).
8. Baecke E, de Koning HJ, Otto SJ, van Iersel CA, van Klaveren RJ: Limited contamination in the Dutch-Belgian randomized lung cancer screening trial (Nelson). Lung Cancer DOI: 10.1016/j.lungcan.2009.08.015 (2009) (Epub ahead of print).
9. Pedersen JH, Ashraf H, Dirksen A et al.: The Danish randomized lung cancer CT screening trial - overall design and results of the prevalence round. J. Thorac. Oncol. 4, 608-614 (2004).
10. Brenner DJ: Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology 231, 440-445 (2004).
11. Diederich S, Wormanns D, Heindel W: Low-dose CT: new tool for screening lung cancer? Eur. Radiol. 11, 1916-1924 (2001).
12. Swensen SJ, Jett JR, Hartman TE, Midthun DE et al.: CT screening for lung cancer: five-year prospective experience. Radiology 235, 259-265 (2005).
13. Revel MP, Merlin A, Peyrard S et al.: Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules. Am. J. Roentgenol. 187, 135-142 (2006).
14. Swensen SJ, Brown LR, Colby TV, Weaver AL: Pulmonary nodules: CT evaluation of enhancement with iodinated contrast material. Radiology 194, 393-398 (1995).
15. Swensen SJ, Brown LR, Colby TV, Weaver AL, Midthun DE: Lung nodule enhancement at CT: prospective findings. Radiology 201, 447-455 (1996).
16. Swensen SJ, Viggiano RW, Midthun DE et al.: Lung nodule enhancement at CT: multicenter study. Radiology 214, 73-80 (2000).
17. Yi CA, Lee KS, Kim EA et al.: Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology 233, 191-199 (2004).
18. Jeong YJ, Lee KS, Jeong SY et al.: Solitary pulmonary nodule: characterization with combined wash-in and washout features at dynamic multi-detector row CT. Radiology 237, 675-683 (2005).
19. Jeong YJ, Yi CA, Lee KS: Solitary pulmonary nodules: detection, characterization, and guidance for further diagnostic workup and treatment. Am. J. Roentgenol. 188(1), 57-58 (2007).
20. Yi CA, Lee KS, Kim BT et al.: Tissue characterization of solitary pulmonary nodule: comparative study between helical CT and integrated PET/CT. J. Nucl. Med. 47(3), 443-450 (2006).
21. Li Y, Yang ZG, Chen TW, Chen HJ, Sun JY, Lu YR: Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. Lung Cancer 61, 44-53 (2008).
22. Ma SH, Jia BH, Wang ZX et al.: Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer 8, 186 (2008).
23. Pastorino U, Bellomi M, Landoni C et al.: Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 362, 593-597 (2003).
24. Bastarrika G, Garcia-Velloso MJ, Lozano MD et al.: Early lung cancer detection using spiral computed tomography and positron emission tomography. Am. J. Respir. Crit. Care Med. 171, 1378-1383 (2005).
25. Gould MK, Kuschner WG, Rydzak CE et al.: Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small cell lung cancer: a meta-analysis. Ann. Intern. Med. 139, 879-892 (2003).
26. Hennebicque AS, Nunes H, Brillet PY, Moulahi H, Valeyre D, Brauner MW: CT in severe sarcoidosis. Eur. Radiol. 15(1), 23-30 (2005).
27. Moon WK, Im JG, Yeon KM, Han MC: Mediastinal tuberculous mediastinitis: CT findings of active and inactive disease. Am. J. Roentgenol. 170(3), 715-718 (1998).
28. Chabert V, Canevet G, Baixas C et al.: Mediastinal lymphadenopathy in congestive heart failure: a sequential CT evaluation with clinical and echocardiographic correlations. Eur. Radiol. 14(5), 881-889 (2004).
29. Bergin CJ, Park KJ: Lymph node enlargement in pulmonary hypertension due to chronic thromboembolism. J. Med. Imaging Radiat. Oncol. 52(1), 18-23 (2008).
30. Sakai O, Curtin HD, Romo LV, Som PM: Lymph node pathology. Benign proliferative, lymphoma, and metastatic disease. Radiol. Clin. North Am. 38(5), 979-998 (2000).
31. Kuhlman JE, Bouchardy L, Fishman EK, Zerhouni EA: CT and MR imaging evaluation of chest wall disorders. Radiographics 14(3), 571-595 (1994).
32. Frericks BB, Meyer BC, Martus P, Wendt M, Wolf KJ, Wacker F: MRI of the thorax during whole-body MRI: evaluation of different MR sequences and comparison to multidetector computed tomography (MDCT). J. Magn. Reson. Imaging 27, 538-545 (2008).
33. Yi CA, Shin KM, Lee KS et al.: Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 248, 632-642 (2008).
34. Schmidt GP, Schoenberg SO, Schmidt R et al.: Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur. Radiol. 17, 939-949 (2006).
35. Remy-Jardin M, Faivre JB, Pontana F et al.: Thoracic applications of dual energy. Radiol. Clin. North Am. 48(1), 193-205 (2010).
36. Chae EJ, Song JW, Seo JB, Krauss B, Jang YM, Song KS: Clinical utility of dual-energy CT in the evaluation of solitary pulmonary nodules: initial experience. Radiology 249, 671-681 (2008).
37. Kawai T, Hara M, Shima K, Ozawa Y, Nakagawa M, Sasaki S: The clinical potential of contrast-mapping images created using the dual-energy CT technique for diagnosing pulmonary lesions. Presented at: The 94th Scientific Assembly and Annual Meeting. Chicago, IL, USA, 30 November-5 December (2008) (Abstract SSCO6-03, 337).
38. Ichikawa T, Ertuk S, Motosuqi U et al.: Virtual PET-MRI as a novel oncologic imaging of the body: principles, techniques and clinical applications. Radiology 776, Abstract 1330BP-e (2005).
39. Cheran SK, Nielsen ND, Patz EFJ: False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. Am. J. Roentgenol. 182, 1129-1132 (2004).
40. Yamamoto Y, Nishiyama Y, Ishikawa S et al.: 3́-deoxy-3́-18F- fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18F-fluoro-d-glucose. J. Comput. Assist. Tomogr. 32, 432-437 (2008).
41. Eschmann SM, Paulsen F, Reimold M et al.: Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J. Nucl. Med. 46, 253-260 (2005).
42. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285, 914-924 (2001).
43. Park SJ, Ionascu D, Killoran J et al.: Evaluation of the combined effects of target size, respiratory motion and background activity on 3D and 4D PET/CT images. Phys. Med. Biol. 53, 3661-3679 (2008).
44. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K: Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size. Ann. Thorac. Surg. 79, 984-988 (2005).
45. Hanin FX, Lonneux M, Cornet J et al.: Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur. J. Cardiothorac. Surg. 33, 819-823 (2008).
46. MacManus M, Hicks RJ: The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. Int. J. Radiat. Oncol. Biol. Phys. 72, 1298-1306 (2008).
47. Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA: Invasive mediastinal staging of lung cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest 132, S202-S220 (2007).
48. Fischer B, Lassen U, Mortensen J et al.: Preoperative staging of lung cancer with combined PET-CT. N. Engl. J. Med. 361, 32-39 (2009).
49. van Tinteren H, Hoekstra OS, Smit EF et al.: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359, 1388-1393 (2002).
50. De Leyn P, Stroobants S, De Wever W et al.: Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J. Clin. Oncol. 24, 3333-3339 (2006).
51. Eschmann SM, Friedel G, Paulsen F et al.: Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 55, 165-171 (2007).
52. Sunaga N, Oriuchi N, Kaira K et al.: Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 59, 203-210 (2008).
53. Krupitskaya Y, Eslamy HK, Nguyen DD, Kumar A, Wakelee HA: Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy. J. Thorac. Oncol. 4, 429-431 (2009).
54. Wahl RL, Jacene H, Kasamon Y, Lodge MA: From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50(Suppl. 1), S122-S150 (2009).
55. Boellaard R: Standards for PET image acquisition and quantitative data analysis. J. Nucl. Med. 50(Suppl. 1), S11-S20 (2009).
56. Woodford C, Yartsev S, Dar AR, Bauman G, van Dyk J: Adaptive radiotherapy planning on decreasing gross tumor volumes as seen on megavoltage computed tomography images. Int. J. Radiat. Oncol. Biol. Phys. 69(4), 1316-1322 (2007).
57. Kupelian PA, Ramsey C, Meeks SL et al.: Serial megavoltage CT imaging during external beam radiotherapy for non-small-cell lung cancer: observations on tumor regression during treatment. Int. J. Radiat. Oncol. Biol. Phys. 63(4), 1024-1028 (2005).
58. Siker ML, Tome WA, Mehta MP: Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy: how reliable, consistent, and meaningful is the effect? Int. J. Radiat. Oncol. Biol. Phys. 66(1), 135-141 (2006).
59. Feng M, Kong FM, Gross M, Fernando S, Hayman JA, Ten Haken RK: Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing: Int. J. Radiat. Oncol. Biol. Phys. 73(4), 1228-1234 (2009).
60. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J: Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 5(9), 531-540 (2004).
61. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME: A tabulated summary of the FDG PET literature. J. Nucl. Med. 42(5 Suppl.), S1-S93 (2001).
62. De Ruysscher D, Wanders S, Minken A et al.: Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother. Oncol. 77(1), 5-10 (2005).
63. Caldwell CB, Mah K, Ung YC et al.: Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int. J. Radiat. Oncol. Biol. Phys. 51(4), 923-931 (2001).
64. Yu HM, Liu YF, Hou M, Liu J, Li XN, Yu JM: Evaluation of gross tumor size using CT, 18F-FDG PET, integrated 18F-FDG PET/CT and pathological analysis in non-small cell lung cancer. Eur. J. Radiol. 72, 104-113 (2009).
65. Black QC, Grills IS, Kestin LL et al.: Defining a radiotherapy target with positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys. 60(4), 1272-1282 (2004).
66. Paulino AC, Koshy M, Howell R, Schuster D, Davis LW: Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 61(5), 1385-1392 (2005).
67. Stroom J, Blaauwgeers H, van Baardwijk A et al.: Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors. Int. J. Radiat. Oncol. Biol. Phys. 69(1), 267-275 (2007).
68. Daisne JF, Duprez T, Weynand B et al.: Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233(1), 93-100 (2004).
69. Nestle U, Kremp S, Schaefer-Schuler A et al.: Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J. Nucl. Med. 46(8), 1342-1348 (2005).
70. van Baardwijk A, Bosmans G, Boersma L et al.: PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int. J. Radiat. Oncol. Biol. Phys. 68(3), 771-778 (2007).
71. van Dalen JA, Hoffmann AL, Dicken V et al.: A novel iterative method for lesion delineation and volumetric quantification with FDG PET. Nucl. Med. Commun 28(6), 485-493 (2007).
72. Daisne JF, Sibomana M, Bol A, Doumont T, Lonneux M, Gregoire V: Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother. Oncol. 69(3), 247-250 (2003).
73. Geets X, Lee JA, Bol A, Lonneux M, Gregoire V: A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur. J. Nucl. Med. Mol. Imaging 34(9), 1427-1438 (2007).
74. Geets X, Tomsej M, Lee JA et al.: Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy. Radiother. Oncol. 85(1), 105-115 (2007).
75. Ling CC, Humm J, Larson S et al.: Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int. J. Radiat. Oncol. Biol. Phys. 47(3), 551-560 (2000).
76. Everitt S, Hicks RJ, Ball D et al.: Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 75(4), 1098-1104 (2009).
77. Thorwarth D, Eschmann SM, Paulsen F, Alber M: Hypoxia dose painting by numbers: a planning study. Int. J. Radiat. Oncol. Biol. Phys. 68(1), 291-300 (2007).
78. Ramsey CR, Langen KM, Kupelian PA et al.: A technique for adaptive image-guided helical tomotherapy for lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 64(4), 1237-1244 (2006).
79. Kong FM, Frey KA, Quint LE et al.: A pilot study of [18F] fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J. Clin. Oncol. 25(21), 3116-3123 (2007).
80. van Baardwijk A, Bosmans G, Dekker A et al.: Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother. Oncol. 82(2), 145-152 (2007).